Trial tests new drug for rare fat disorder
NCT ID NCT06548100
Summary
This study is testing the safety of switching patients with a rare disorder called generalized lipodystrophy from their current medication to an experimental new drug called mibavademab. It involves a small group of 9 participants who have been stable on their current treatment. The main goal is to see if the new drug is safe and well-tolerated, while also checking its effects on blood sugar and fat levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health
Bethesda, Maryland, 20892, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.